Results 1 to 10 of 34 matches
Category 5 - DIAGNOSTIC IMAGING SERVICES
61333 - Additional Information
Lung ventilation study using Galligas and lung perfusion study using gallium-68 macro aggregated albumin (68Ga-MAA), with PET, if the service is performed because the service to which item 61348 applies cannot be performed due to unavailability of technetium-99m (R)
Fee: $443.35 Benefit: 75% = $332.55 85% = $376.85
(See para IN.4.4 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61336 - Additional Information
Cerebral study, with PET, if the service is performed because the service to which item 61402 applies cannot be performed due to unavailability of technetium-99m (R)
Fee: $605.05 Benefit: 75% = $453.80 85% = $514.30
(See para IN.4.4 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61341 - Additional Information
Bone study – whole body with PET, with delayed imaging when undertaken, if the service is performed because the services to which item 61421 or 61425 apply cannot be performed due to unavailability of technetium-99m (R)
Fee: $600.70 Benefit: 75% = $450.55 85% = $510.60
(See para IN.4.4 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61523 - Additional Information
Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.(R)
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61524 - Additional Information
Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for a patient who is considered suitable for active therapy (R)
(Anaes.)
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61525 - Additional Information
Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R)
(Anaes.)
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61527 - Additional Information
Whole body study using PET, if the service is performed because the services to which items 61429, 61430, 61442, 61450 or 61453 apply cannot be performed due to unavailability of gallium-67 (R)
Fee: $752.35 Benefit: 75% = $564.30 85% = $647.85
(See para IN.4.4 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61528 - Additional Information
Whole body PSMA PET study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor.
(R)
(Anaes.)
Fee: $1,300.00 Benefit: 75% = $975.00 85% = $1,195.50
Category 5 - DIAGNOSTIC IMAGING SERVICES
61529 - Additional Information
Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned (R)
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
(See para IN.0.19 of explanatory notes to this Category)
Category 5 - DIAGNOSTIC IMAGING SERVICES
61530 - Additional Information
Whole body 68Ga-DOTA-somatostatin receptor agonist PET study for:
a) staging of histologically confirmed neuroendocrine neoplasm (NEN) considered surgically incurable on conventional imaging, or
b) evaluation of somatostatin receptor expression of histologically confirmed and inoperable NEN, either locally advanced or metastatic, under consideration for peptide receptor radionuclide therapy (PRRT); or
c) evaluation of response to PRRT therapy; or
d) evaluation of suspected recurrent or metastatic disease in known somatostatin receptor positive NEN.
(R)
(Anaes.)
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
Results 1 to 10 of 34 matches
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change